AMENDED FORM 9. NOTICE OF PROPOSED ISSUANCE OF LISTED SECURITIES (or securities convertible or exchangeable into listed securities 1 )

Transcription

1 AMENDED FORM 9 NOTICE OF PROPOSED ISSUANCE OF (or securities convertible or exchangeable in listed securities 1 ) Please complete the following: Name of Listed Issuer: IMAGIN MEDICAL INC. (the Issuer ). Trading Symbol: IME Date: Ocber 13, 2017 Is this an updating or amending Notice: Yes No If yes provide date(s) of prior Notices: September 29, 2017 & Ocber 4, 2017 (This Amended Form 9 includes final particulars of Tranche 1 and Tranche 2 of this private placement.) Issued and Outstanding of Issuer Prior Issuance: 64,139,429 Date of News Release Announcing Private Placement: September 26, 2017 Closing Market Price on Day Preceding the Issuance of the News Release: $ Private Placement (if shares are being issued in connection with an acquisition (either as consideration or raise funds for a cash acquisition), proceed Part 2 of this form). This table includes Tranche 1 and Tranche 2 of the Issuer s private placement. Full Name & or be, Roger Luke Buckley 4 Bingham Avenue M4E 3P9 204,432 Sep 22/17 Roger Buckley PH8-9 Boardwalk Drive M4L 6T1 3,500,000 $0.05 3,621,000 Sep 25/17 & Oct 3/17 Page 1

2 Full Name & or be, Robert Philip Buckley Apt. # avenue du Parc Montréal, Québec H2V 4H2 280,000 $ ,000 Sep 25/17 Brian Flynn 987 Pape Avenue M5K 3V6 60,000 $ ,000 Sep 25/17 Rod Lobraico 34 Davies Crescent M4J 2X5 100,000 $ ,000 Sep 25/17 Marc Buckley 4 Bingham Avenue M4E 3P9 2.5(1) of NI 201,000 Sep 25/17 Jon Buckley Stadium Road M5V 3P4 201,000 Sep 25/17 Rick Forsayeth 40 Strathcona Avenue M5K 1K7 120,000 $ ,538 Sep 25/17 Jorge Avelino 1107 Madore Avenue Coquitlam, V3K 3C1 360,000 $ (1) of NI 360,000 Oct 2/17 Officer William Galine 4220 Bond Creek Court Reno, NV ,000 $ (1) of NI 2,200,000 Sep 29/17 Direcr & Officer Edmund Obasi 308 Panora Close NW Calgary, AB T3K 0G3 1,000,000 $ (1) of NI 1,000,000 Sep 29/17. & Oct 4/17 Brian Blakeley 2121 Rathburn Rd E Apt 903, Mississauga ON L4W 2x3 100,000 $ ,000 Sep 28/17 Page 2

3 Full Name & or be, Golden Capital Consulting Ajeltake Road Majuro, Ajeltake Islands Marshall Islands Juozas Papartis, Direcr 1,000,000 $0.05 1,500,000 Oct 2/17 Vicria Stein 1111 Avenue Road Suite 212 M5N 3B2 204,000 Oct 3/17 Peter Adamek 20 Harrison Avenue Mississauga, ON L5H 2N9 2.3(1)(k) of NI 200,000 Oct 2/17 D. Bruce Letvak 841 Pembern Rd Vicria, V8S 3R5 500,000 $ ,000 Oct 2/17 Sandy Cabrita 2336 Mary Hill Road Port Coquitlam, V3C 3A7 100,000 $ ,000 Oct 10/17 Sheila Boyle 594 Washingn Street Unit 3 Wellesley, MA ,800 $ ,800 Oct 3/17 Gerhard Merkel Almecen 50G Independencia, 5350 Paraguay 225,000 Oct 10/17 Jean-David Moore 4661 Clara Brousseau, Quebec, QC G1Y 3M9 300,000 Oct 3/17 Rob Gagnon Thurlow St Vancouver V6E 1X4 598,000 Oct 3/17 Gordon Holmes Granville St Vancouver, V7Y 1H2 600,000 $ ,000 Oct 10/17 Page 3

4 Full Name & Kulwant Malhi Ladner Trunk Rd, Delta V4G 1K2 Frank Hoegel 5350 Independencia Guara, Paraguay Karim Mohamedani 5821 Pioneer Ave, Burnaby V5H 2X8 Justin Vlietstra 111 Childerhose Cres. Brantford, ON N3P 1Z6 Angel Valov 138 Bonis Ave, Unit 1826, Sutn Ventures Monte Vista Dr, Chilliwack V2R ST2 Robert Smalley 11 Haysboro Cres SW, Calgary, AB T2V 3G1 Randy Lamb 314 Robertson Ave Box 762 West Foam Lake, SK S0A Axel Reuer Dachsbergstr 25 Brackeneim BV 74336, Germany or be 500,000 $ ,000 $ ,000 $0.05 1,000,000 $ (1)(j) and (k) of NI 2.3(1)(k) of NI, 1,500,000 Oct 10/17 340,000 Oct 3/17 100,000 Oct 10/17 400,000 Oct 10/17 1,000,000 Oct 3 & Oct 4/17 2.3(1) of NI 200,000 Oct 10/17 2.3(1)(j) & (k) of NI 1,000,000 $ ,000 shares & 125,000 warrants Oct 4/17 1,200,000 Sep 28/17 210,000 Oct 2/17 Lorne Torhjelm Street Surrey, V4A 9T8 Sean O Connor 15 Lagoon Avenue Hamiln, ON L8H 7C4 David Edmondson 6249 Garside Rd Nanaimo, V9T 6H9 400,000 $ ,000 $ (1)(k) of NI 2.5(1)(d) of NI Page 4 800,000 Oct 3/17 800,400 Oct 4/17 200,000 Oct 4/17

5 Full Name & Steven Feldman A Avenue Surrey, V4P 0C2 Rob Ryan 1545 Narva Rd. Mississauga, ON L5H 3H4 Rod Lobraico 34 Davies Cres. M4J 2X5 Klaus Stark 152 M Kram, Klaeng Rayong 21990, Thailand Don Nicolson 638 Cliff Road Bowen Island, V0N 1G1 R. Ronald Schnier # Garland Rd. Dallas, TX Ronald Worobec 1012 Bonehomme Street P.O. Box 2898 Jasper, AB T0E 1E0 James Grant 53 Benningn Hts. Dr. M4G 1A8 Stanley J. Swierzewski III 272 Shaker Rd. Longmeadow, MA Monique Lunde th Ave W Vancouver, V6J 2C5 Joshua Lafferty 2553 Loseth Rd Kelowna, V1P 1S6 or be 2.3(1)(e.1) of NI 2.3(1)(k) of NI 100,000 $ (1)(d) of NI 616,760 $ ,000 $ (1)(j) and (k) of NI 100,000 $ ,040 $ ,000 $ ,000 $0.05, 200,000 Oct 4/17 300,000 Oct 4/17 110,000 Oct 4/17 240,000 Oct 4/17 300,000 Oct 4/17 616,760 Oct 5/17 500,000 Oct 5/17 125,000 Oct 5/17 244,040 Oct 6/17 230,000 DAP 125,000 DAP Page 5

6 Full Name & Rolar Consulting Inc th Ave W Vancouver, V6J 2C5 Robert Lunde, President Sutn Ventures Ltd Monte Vista Dr. Chilliwack, V2R 5T2 Brayden Sutn, President Tyler Lunde 1848 West 11th Ave Vancouver, V6J 2C5 Madeleine Lunde 1848 West 11th Ave Vancouver, V6J 2C5 Derek A. Husn Aldercrest Dr. North Vancouver, V7G 0A2 Claimbank Exploration Inc Marine Drive S.E. Vancouver, V5S 2H Jason Barnard, President Sven Olsson Ochslinstrabe Goppingen, Germany or be 600,000 $ (1)(d) of NI 2.3(1)(t) of NI 100,000 $ ,000 $ ,400 $ (1) (j) of NI, 1,165,500 DAP 200,000 DAP 203,000 Oct 11/17 90,000 Oct 11/17 200,000 Oct 11/17 2,630,400 Oct 12/17 250,000 Oct 4/17 TOTAL SUBSCRIPTIONS RECEIVED TO DATE 20,000,000 (1) Indicate date each placee advanced or is expected advance payment for securities. Provide details of expected payment date, conditions release of funds etc. Indicate if the placement funds been placed in trust pending receipt of all necessary approvals. (2) Indicate if Related Person. Page 6

7 1 An issuance of non-convertible debt does not have be reported unless it is a significant transaction as defined in Policy 7, in which case it is be reported on Form Total amount of funds be raised: $1,000, Provide full details of the use of the proceeds. The disclosure should be sufficiently complete enable a reader appreciate the significance of the transaction without reference any other material. General working capital and the advancement of the Company s efforts develop imaging solutions for the early detection of cancer.. 3. Provide particulars of any proceeds which are be paid Related Persons of the Issuer: N/A 4. If securities are issued in forgiveness of indebtedness, provide details and attach the debt agreement(s) or other documentation evidencing the debt and the agreement exchange the debt for securities. N/A 5. Description of securities be issued: (a) (b) Class Units comprised of common shares & warrants. Number 20,000,000 Units (c) Price per security $0.05 per Unit (d) Voting rights each common share is entitled one vote Page 7

8 6. Provide the following information if Warrants, (options) or other convertible securities are be issued: (a) Number 20,000,000 warrants. (b) securities eligible be purchased on exercise of Warrants (or options) 20,000,000 shares (c) Exercise price $0.10 for a period of 12 months.. (d) Expiry date 12 months after closing 7. Provide the following information if debt securities are be issued: N/A (a) Aggregate principal amount. (b) Maturity date. (c) Interest rate. (d) terms. (e) Default provisions. 8. Provide the following information for any agent s fee, commission, bonus or finder s fee, or other compensation paid or be paid in connection with the placement (including warrants, options, etc.): (a) (b) Details of any dealer, agent, broker or other person receiving compensation in connection with the placement (name, address. If a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known the Issuer): Finder s fees were paid Patrick Georgetti, with address at 18 Parkview Hill Cr., Toron, Ontario, M4B 1P6 Cash A tal of $20,240 ($19,840 for Tranche 1 and $400 for Tranche 2) (c) A tal of 404,400 warrants (396,800 warrants for Tranche 1 and 8,000 warrants for Tranche 2), each warrant exercisable at $0.10 for a period of 12 months. (d) Other. (e) Expiry date of any options, warrants etc. 12 months from the date of issue (f) Exercise price of any options, warrants etc. $0.10. Page 8

9 9. State whether the sales agent, broker, dealer or other person receiving compensation in connection with the placement is Related Person or has any other with the Issuer and provide details of the 10. any unusual particulars of the transaction (i.e. tax flow through shares, etc.). NOT APPLICABLE 11. State whether the private placement will result in a change of control. The private placement will not result in a change of control. 12. Where there is a change in the control of the Issuer resulting from the issuance of the private placement shares, indicate the names of the new controlling shareholders Each purchaser has been advised of the applicable securities legislation restricted or seasoning period. All certificates for securities issued which are subject a hold period bear the appropriate legend restricting their transfer until the expiry of the applicable hold period required by National Acquisition NOT APPLICABLE 1. Provide details of the assets be acquired by the Issuer (including the location of the assets, if applicable). The disclosure should be sufficiently complete enable a reader appreciate the significance of the transaction without reference any other material: N/A. 2. Provide details of the acquisition including the date, parties and type of agreement (eg: sale, option, license etc.) and the Issuer. The disclosure should be sufficiently complete enable a reader appreciate the significance of the acquisition without reference any other material: 3. Provide the following information in relation the tal consideration for the acquisition (including details of all cash, securities or other consideration) and any required work commitments: (a) Total aggregate consideration in Canadian dollars:. (b) Cash:. (c) (including options, warrants etc.) and dollar value: Page 9

10 (d) Other:. (e) Expiry date of options, warrants, etc. if any:. (f) Exercise price of options, warrants, etc. if any:. (g) Work commitments:. 4. State how the purchase or sale price was determined (e.g. arm s-length negotiation, independent committee of the Board, third party valuation etc).. 5. Provide details of any appraisal or valuation of the subject of the acquisition known management of the Issuer:. 6. The names of parties receiving securities of the Issuer pursuant the acquisition and the number of securities be issued are described as follows: Name of Party (If not an individual, name all insiders of the Party) Number and Type of be Issued Dollar value per price (if applicable), by Party Issuer (1) (1) Indicate if Related Person 7. Details of the steps taken by the Issuer ensure that the vendor has good title the assets being acquired: 8. Provide the following information for any agent s fee, commission, bonus or finder s fee, or other compensation paid or be paid in connection with the acquisition (including warrants, options, etc.): (a) Details of any dealer, agent, broker or other person receiving compensation in connection with the acquisition (name, address. If a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known the Issuer): (b) Cash. Page 10

11 (c). (d) Other. (g) Expiry date of any options, warrants etc. (h) Exercise price of any options, warrants etc.. 9. State whether the sales agent, broker or other person receiving compensation in connection with the acquisition is a Related Person or has any other with the Issuer and provide details of the. 10. If applicable, indicate whether the acquisition is the acquisition of an interest in property contiguous or otherwise related any other asset acquired in the last 12 months.. Certificate Of Compliance The undersigned hereby certifies that: 1. The undersigned is a direcr and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of direcrs of the Issuer sign this Certificate of Compliance on behalf of the Issuer. 2. As of the date hereof there is not material information concerning the Issuer which has not been publicly disclosed. 3. The undersigned hereby certifies the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National ) and all Exchange Requirements (as defined in CSE Policy 1). 4. All of the information in this Form 9 Notice of Issuance of is true. Dated Ocber 13, 2017 JORGE AVELINO Name of Direcr or Senior Officer Signature CFO Official Capacity Page 11